Overview

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin

Status:
Completed

Trial end date:
2005-08-01

Target enrollment:

Participant gender:

Summary

This study is designed to compare the effects of twice-daily exenatide plus oral antidiabetic (OAD) agents and twice-daily placebo plus OAD with respect to glycemic control, as measured by hemoglobin A1c (HbA1c), in patients with type 2 diabetes who experience inadequate glycemic control with OAD alone.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Eli Lilly and Company

Treatments:

2,4-thiazolidinedione
Exenatide
Metformin